ArticleNature communications2019
A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Frailty in People with HIV Is Linked to Inflammation, Bone Health, and T-Cell Exhaustion.The Journal of infectious diseases · 2026Article
- KLF6 activation marks an angiogenic and apoptosis resistant endothelial phenotype in pulmonary arterial hypertension.Communications biology · 2026Article
- Blood pressure, proteomic vascular ageing, and incident cardiovascular disease.European journal of preventive cardiology · 2026Article
- Circulating inflammatory proteins predict dementia risk, and are linked to structural brain changes and modifiable risk factors.Alzheimer's research & therapy · 2026Article
- Osteoprotegerin-Enabled Immune Evasion of Pathological Adipose Stromal Cells Drives Metabolic Dysfunction in Obesity.bioRxiv : the preprint server for biology · 2026Article
- Osteoprotegerin is induced by transforming growth factor-beta 1 and regulates pro-fibrotic responses in human dermal fibroblasts.Biochemical and biophysical research communications · 2025Article
- The Role of Osteoprotegerin in Breast Cancer: Genetic Variations, Tumorigenic Pathways, and Therapeutic Potential.Cancers · 2025Review
- A humanized monoclonal antibody targeting an ectonucleotidase rescues cardiac metabolism and heart function after myocardial infarction.Cell reports. Medicine · 2024Article
- Ambulatory Blood Pressure in Patients With Rheumatoid Arthritis: Association With Immune Activation.The Journal of rheumatology · 2024Article
- Identification of pyroptosis-associated genes with diagnostic value in calcific aortic valve disease.Frontiers in cardiovascular medicine · 2024Article
- Plasma TRAIL and ANXA1 in diagnosis and prognostication of pulmonary arterial hypertension.Pulmonary circulation · 2023Article
- Emerging biologics for the treatment of pulmonary arterial hypertension.Journal of drug targeting · 2023Review
- Delayed denervation-induced muscle atrophy inFrontiers in physiology · 2023Article
- Causal effects for genetic variants of osteoprotegerin on the risk of acute myocardial infarction and coronary heart disease: A two-sample Mendelian randomization study.Frontiers in cardiovascular medicine · 2023Article
- The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure.Circulation research · 2022Review
- Pachymic Acid Ameliorates Pulmonary Hypertension by Regulating Nrf2-Keap1-ARE Pathway.Current medical science · 2022Article
- Roles of osteoprotegerin in endocrine and metabolic disorders through receptor activator of nuclear factor kappa-B ligand/receptor activator of nuclear factor kappa-B signaling.Frontiers in cell and developmental biology · 2022Review
- Frataxin and endothelial cell senescence in pulmonary hypertension.The Journal of clinical investigation · 2021Article
- Altered Macrophage Polarization Induces Experimental Pulmonary Hypertension and Is Observed in Patients With Pulmonary Arterial Hypertension.Arteriosclerosis, thrombosis, and vascular biology · 2021Observational
- Antiresorptive activity of osteoprotegerin requires an intact heparan sulfate-binding site.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 7 institutions in 2 countries.
Funding
Abstract
Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Current treatments increase life expectancy but have limited impact on the progressive pulmonary vascular remodelling that drives PAH. Osteoprotegerin (OPG) is increased within serum and lesions of patients with idiopathic PAH and is a mitogen and migratory stimulus for pulmonary artery smooth muscle cells (PASMCs). Here, we report that the pro-proliferative and migratory phenotype in PASMCs stimulated with OPG is mediated via the Fas receptor and that treatment with a human antibody targeting OPG can attenuate pulmonary vascular remodelling associated with PAH in multiple rodent models of early and late treatment. We also demonstrate that the therapeutic efficacy of the anti-OPG antibody approach in the presence of standard of care vasodilator therapy is mediated by a reduction in pulmonary vascular remodelling. Targeting OPG with a therapeutic antibody is a potential treatment strategy in PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.